FDA’s ODAC Concerned About Off-Label, Long-Term Promacta Use
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline’s ITP treatment gets panel review May 30 onsite at ASCO.
You may also be interested in...
ODAC Unanimously Recommends GSK’s Promacta For ITP
FDA, committee members struggle to find ways to discourage long-term use of the drug for the chronic condition.
ODAC Unanimously Recommends GSK’s Promacta For ITP
FDA, committee members struggle to find ways to discourage long-term use of the drug for the chronic condition.
Amgen’s Platelet Booster Faces FDA Panel
Risk management plan is likely focus of March 12 ODAC meeting.